Stocksigma LogoStocksigma Logo

Cipla Secures Exclusive US Licensing for Keytruda Biosimilar from Qilu Pharmaceutical

On 3rd Sep'26, Cipla announced an exclusive US licensing and supply partnership with Qilu Pharmaceutical for QL2107, a biosimilar to Keytruda

Cipla Secures Exclusive US Licensing for Keytruda Biosimilar from Qilu Pharmaceutical

Cipla Ltd 路 Press Release 路 04 Sept 2026, 1:36 am

Cipla Secures Exclusive US Licensing for Keytruda Biosimilar from Qilu Pharmaceutical On 3rd Sep'26, Cipla announced an exclusive US licensing and supply partnership with Qilu Pharmaceutical for QL2107, a biosimilar to Keytruda (pembrolizumab). Under the agreement, Qilu assumes responsibility for development, regulatory registration, and manufacturing supply, while Cipla USA secures commercialization rights. This partnership enables Cipla to leverage its existing US commercial infrastructure to expand its oncology-focused biosimilar portfolio. The strategic addition of this asset significantly strengthens Cipla's US pipeline, positioning the company to capture share in a high-value market upon regulatory approval.

Original exchange filing (PDF)

More announcements from Cipla Ltd

All Cipla Ltd announcements